CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website https://www.carsgen.com.
The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: https://doi.org/10.1016/S0140-6736(25)00860-8.
The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)".
Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures."
Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients."
About Satri-cel
Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595).
Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA.
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.
Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.
Contact CARsgen
For more information, please visit https://www.carsgen.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/carsgen-presents-research-results-on-satri-cel-in-the-lancet-and-at-the-2025-asco-annual-meeting-302470028.html
SOURCE CARsgen Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Sterilization Equipment Market to Reach $29.2 Billion by 2032, Growing at a CAGR of 8.2% from 2025, Says Meticulous Research®
Market Growth Driven by Rising Hospital-Acquired Infections, Increasing Surgical Procedures, Enhanced Food Industry Sterilization Focus, and Growing Pharmaceutical & Biotechnology Demand REDDING, Calif., June 30, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Sterilization Equipment Market Size, Share, Forecast, & Trends Analysis by Offering (Equipment [Heat {Moist (Gravity, High-speed), Dry (Static Air, Forced Air)}, Low-temperature {ETO, Formaldehyde}, Radiation, Filtration] Services - Global Forecast to 2032", the Sterilization Equipment market is projected to reach $29.2 billion by 2032, up from an estimated $16.8 billion in 2025, growing at a robust CAGR of 8.2% during the forecast period. The growth of the sterilization equipment market is primarily driven by the increasing prevalence of hospital-acquired infections, a rise in surgical procedures, and an enhanced focus on sterilization within the food industry to mitigate food-borne illnesses. Additionally, there is growing demand for sterilization equipment from pharmaceutical and biotechnology sectors, alongside a trend toward outsourcing sterilization processes to specialized service providers in non-healthcare industries. The industry is experiencing revolutionary transformation through advanced technology integration, including AI and robotics adoption, ozone sterilization innovations, and development of carbon dioxide (CO2) sterilization alternatives to ethylene oxide. Leading companies are embracing digital sterilization technologies while expanding into emerging markets and developing innovative solutions for complex sterilization challenges across healthcare and non-healthcare sectors. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Advanced Sterilization Excellence The sterilization equipment market represents a paradigm shift in infection control and contamination prevention across multiple industries. As healthcare facilities increasingly prioritize patient safety while pharmaceutical and biotechnology companies seek specialized sterilization expertise, advanced sterilization equipment offers a revolutionary solution that addresses the growing demand for effective, efficient, and environmentally sustainable sterilization processes. Market leaders are investing heavily in next-generation sterilization technologies and automated systems, establishing capabilities that can deliver scalable, reliable sterilization solutions. This technological advancement is making sophisticated sterilization processes increasingly accessible while delivering superior microbial reduction and operational efficiency benefits. Dynamic Growth Across Key Market Segments Based on offering, the Equipment segment dominates the market in 2025, capturing approximately 55% of the total market share due to rising incidence of hospital-acquired infections, high adoption of sterilization equipment in medical devices and pharmaceutical industries, and increasing need to ensure safety of food & beverages. The Services segment is experiencing significant growth driven by outsourcing trends and specialized sterilization requirements. Based on end users, the Hospitals & Clinics segment leads the market with approximately 35.9% share, reflecting the high prevalence of HAIs, rising number of surgical procedures, growing demand for clean and quality healthcare facilities, and increasing burden of chronic diseases associated with an aging population. According to the World Health Organization (WHO), out of every 100 patients in acute care hospitals, seven patients in high-income countries and 15 patients in low- and middle-income countries will be affected by at least one healthcare-acquired infection during their hospital stay. The Medical Device Companies segment is also experiencing robust growth, driven by stringent regulatory requirements and the need for specialized sterilization processes for complex medical devices and instruments. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through advanced technology integration, emerging market expansion, and development of environmentally sustainable sterilization solutions. Companies are discovering new revenue streams through CO2 sterilization capabilities, ozone sterilization technologies, and comprehensive infection control ecosystems. Key market drivers include: Rising Hospital-Acquired Infections: Increasing prevalence of HAIs compelling healthcare facilities to invest in advanced sterilization equipment and protocols to ensure patient safety and regulatory compliance Advanced Sterilization Technologies: Integration of AI, robotics, ozone generation, and supercritical CO2 systems enhancing efficiency, precision, and environmental sustainability in sterilization processes Pharmaceutical & Biotechnology Growth: Expanding demand from pharmaceutical and biotechnology industries for specialized sterilization solutions supporting complex biologics manufacturing and sterile processing environments Food Industry Safety Focus: Growing emphasis on food safety and prevention of food-borne illnesses driving adoption of advanced sterilization equipment in food & beverage processing facilities Regional Market Leadership and Emerging Growth North America commands the largest market share in 2025 with approximately 46% of the global market, driven by growing hospital & outpatient visits, rising number of surgical procedures, growing incidence of HAIs, increasing healthcare expenditure, growth in pharma & biotech industries, and government initiatives to reduce HAIs and implement effective sterilization practices. Asia-Pacific emerges as a high-growth region with significant potential, propelled by expanding healthcare infrastructure, rising quality standards in manufacturing, government initiatives for healthcare modernization, and growing awareness of infection control measures across various industries. Europe represents a substantial market, supported by stringent regulatory frameworks, advanced healthcare systems, growing demand for specialized sterilization solutions, and presence of leading sterilization equipment manufacturers with emphasis on innovation and compliance. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global sterilization equipment market features an innovative competitive ecosystem comprising specialized sterilization equipment manufacturers, healthcare technology companies, and integrated solution providers. This diverse landscape fosters rapid technological advancement through cutting-edge automation integration and specialized sterilization expertise development. Industry leaders are implementing comprehensive solutions that combine advanced sterilization technologies with monitoring systems, validation services, and regulatory compliance capabilities. Companies are pursuing strategic partnerships and acquisitions while addressing scalability and environmental sustainability challenges across different industry segments. Latest Industry Developments Recent market developments include: Advanced Low-Temperature Sterilization: Launch of innovative low-temperature sterilizers designed for heat-sensitive surgical instruments with advanced cross-contamination barrier technology EU GMP Compliance Solutions: Introduction of specialized sterilization bags and covers supporting EU GMP Annex 1 compliance for biopharmaceutical companies Nitrogen Dioxide Innovation: Expansion of sterilization service portfolios through nitrogen dioxide gas technology offering enhanced microbial efficacy and environmental benefits Steam Monitoring Advancement: Development of comprehensive steam monitoring products including biological indicators, chemical indicators, and indicator tapes for enhanced sterile processing confidence Market Challenges and Revolutionary Solutions While the market shows strong growth potential, it faces challenges including adverse effects associated with ethylene oxide usage, safety concerns regarding instrument reprocessing, complex regulatory compliance requirements, and environmental sustainability pressures. However, significant opportunities exist through rising adoption of e-beam sterilization, growing demand in emerging markets, increasing utilization of CO2 sterilization technology, and enhanced focus on infection control across healthcare and non-healthcare sectors. The shift from reusable to disposable medical devices presents both challenges and opportunities, as manufacturers adapt their sterilization strategies while healthcare facilities balance cost-effectiveness with infection prevention requirements. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global sterilization equipment market include STERIS plc (U.S.), 3M Company (U.S.), Getinge AB (Sweden), Cardinal Health, Inc. (U.S.), Advanced Sterilization Products, Inc. (U.S.) (A subsidiary of Fortive Corporation), Fedegari Autoclavi SpA (Italy), Stryker Corporation (U.S.), ANTONIO MATACHANA, S. A. (Spain), SteelcoBelimed AG (Switzerland), Sotera Health Company (U.S.), Benchmark Scientific Inc (U.S.), MMM Münchener Medizin Mechanik GmbH (Germany), Tuttnauer (Netherlands), Consolidated Sterilizer Systems (U.S.), and Andersen Sterilizers, Inc. (U.S.). These companies are focusing on strategies such as advanced automation technology integration, environmentally sustainable sterilization solution development, comprehensive service portfolio expansion, strategic partnerships and acquisitions, and geographic expansion into emerging markets to strengthen their market position. Related Reports: Medical Device Contract Manufacturing Market Pharmaceutical Contract Development and Manufacturing Market Pharmaceutical Processing Equipment Market Disinfection Robots Market Size, Share, Forecast, & Trends Microbial Control Chemical Market by Size, Share About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Our Website: with us on LinkedIn- Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd.
Yahoo
an hour ago
- Yahoo
Autoimmune Disease Diagnostics Market to Reach $11.45 Billion by 2032, Growing at a CAGR of 7.5% from 2025, Says Meticulous Research®
Market Growth Driven by Rising Prevalence of Autoimmune Disorders, Emphasis on Early Diagnosis, Advanced Biosensor Technologies, and Growing Healthcare Awareness REDDING, Calif., June 30, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Autoimmune Disease Diagnostics Market Size, Share, Forecast, & Trends Analysis By Product (Reagents, Kits, Assays, Instruments), Test Type (ANA, CRP, ESR, Rheumatoid Factor, Routine Test), Disease Type (Systemic, Localized) - Global Forecast to 2032," the Autoimmune Disease Diagnostics market is projected to reach $11.45 billion by 2032, up from an estimated $6.91 billion in 2025, growing at a robust CAGR of 7.5% during the forecast period. The growth of the autoimmune disease diagnostics market is driven by the increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune diseases. The market's expansion is fueled by advanced biosensor technologies, sophisticated diagnostic solutions, and the critical need for rapid and accurate detection of autoimmune conditions across diverse patient populations. The industry is experiencing revolutionary transformation through the integration of cutting-edge biosensor technologies, AI-powered diagnostic platforms, and development of highly specific biomarker detection systems. Leading companies are embracing digital diagnostic solutions while expanding into emerging markets and developing innovative point-of-care testing capabilities for healthcare providers worldwide. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Advanced Diagnostic Excellence The autoimmune disease diagnostics market represents a paradigm shift in healthcare delivery and patient outcomes optimization. As healthcare providers increasingly prioritize early detection and accurate diagnosis of complex autoimmune conditions, advanced diagnostic solutions offer a revolutionary approach that addresses the growing demand for cost-effective, highly sensitive, and technologically sophisticated autoimmune disease detection capabilities. Market leaders are investing heavily in biosensor technologies and biomarker research, establishing diagnostic capabilities that can deliver rapid, accurate, and patient-specific autoimmune disease detection. This technological advancement is making sophisticated autoimmune diagnostics increasingly accessible while delivering superior accuracy and clinical outcomes benefits. Dynamic Growth Across Key Market Segments Based on product type, the Reagents, Assays, & Kits segment dominates the market in 2025, capturing approximately 84% of the total market share due to high diagnosis rates of autoimmune diseases in developed countries, recurring purchase patterns, and growing availability of convenient diagnostic solutions. This segment is also experiencing the fastest growth with 7.4% CAGR, driven by increasing product launches, cost-effectiveness, and ease of use in clinical settings. Based on test type, the Antinuclear Antibodies (ANA) segment leads the market, reflecting its critical role in early detection of autoimmune diseases, high sensitivity for primary screening, and widespread clinical adoption. This segment is anticipated to record the highest growth rate of 8.3% during the forecast period, driven by the advantages of ANA testing including early disease detection capabilities and comprehensive autoimmune screening benefits. Based on disease type, the Systemic Autoimmune Diseases segment accounts for the larger market share, attributed to high prevalence of conditions like rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus affecting multiple organ systems. This segment is expected to maintain strong growth throughout the forecast period. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through biosensor technology integration, emerging market expansion, and development of specialized point-of-care diagnostic solutions. Companies are discovering new revenue streams through advanced biomarker detection capabilities and comprehensive diagnostic service portfolios while establishing integrated autoimmune disease management ecosystems. Key market drivers include: Rising Disease Prevalence: Increasing incidence of autoimmune disorders globally, with approximately 24 million people in the U.S. suffering from autoimmune diseases, driving demand for accurate diagnostic solutions Early Diagnosis Emphasis: Growing recognition of the importance of early detection in reducing disability, morbidity, and mortality associated with autoimmune diseases Advanced Biosensor Technologies: Integration of sophisticated biosensor platforms utilizing antibodies, antigens, and peptides for highly specific biomarker detection and improved diagnostic accuracy Healthcare Awareness Growth: Expanding public and healthcare provider awareness about autoimmune diseases, supported by initiatives from organizations like the Autoimmune Association promoting education and early intervention Regional Market Leadership and Emerging Growth North America commands the largest market share in 2025 with approximately 39% of the global market, driven by high prevalence of autoimmune diseases, advanced diagnostic infrastructure, presence of leading diagnostic companies, and significant healthcare expenditure supporting widespread adoption of sophisticated diagnostic technologies. Asia-Pacific emerges as the fastest-growing region with a projected CAGR of 9.7% during 2025-2032, propelled by increasing prevalence of celiac disease and rheumatoid arthritis, adoption of unhealthy lifestyles due to urbanization, government initiatives addressing autoimmune diseases, and rising investments in autoimmune disease research and diagnostic capabilities. Europe represents a significant market, supported by advanced healthcare systems, strong regulatory frameworks, growing demand for precision diagnostics, and presence of leading diagnostic technology providers with emphasis on quality and clinical accuracy. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global autoimmune disease diagnostics market features an innovative competitive ecosystem comprising specialized diagnostic companies, biotechnology firms, and integrated healthcare technology providers. This diverse landscape fosters rapid technological advancement through sophisticated biosensor integration and specialized biomarker research development. Industry leaders are implementing integrated solutions that combine advanced diagnostic technologies with comprehensive testing portfolios and quality assurance capabilities. Companies are pursuing strategic partnerships and acquisitions while addressing scalability and accessibility challenges across different healthcare settings and patient populations. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global autoimmune disease diagnostics market include Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.). These companies are focusing on strategies such as advanced biosensor technology development, comprehensive diagnostic portfolio expansion, point-of-care testing solutions, strategic partnerships and acquisitions, and geographic expansion into emerging markets to strengthen their market position and enhance diagnostic accessibility. Latest Industry Developments Recent market developments include: Biosensor Technology Advancement: Development of innovative biosensor platforms for rapid, sensitive, and cost-effective autoimmune disease detection using electrochemical, piezoelectric, and optical sensing technologies Biomarker Research Integration: Enhanced focus on autoantibody (AAb) detection and other specific biomarkers including chemokines, cytokines, and proteins for improved diagnostic accuracy and disease monitoring Point-of-Care Solutions: Strategic initiatives to develop portable and user-friendly diagnostic devices enabling rapid testing in hospitals, clinics, and healthcare facilities Market Challenges and Opportunities While the market shows strong growth potential, it faces challenges including difficulties in accurate diagnosis of autoimmune diseases due to complex symptom patterns, unfavorable reimbursement scenarios in certain regions, high rates of delayed diagnosis or misdiagnosis, and regulatory compliance requirements across different jurisdictions. However, significant opportunities exist in expanding biosensor technology adoption, growing healthcare expenditure in developing countries, increasing demand for personalized diagnostic solutions, emerging applications in digital health and connected diagnostic devices, and rising need for specialized diagnostic expertise in complex autoimmune conditions. The diagnostic laboratories segment continues to dominate due to skilled workforce availability, high-throughput processing capabilities, and advanced instrumentation. However, the hospitals & clinics segment is projected to experience the highest growth, driven by increasing adoption of point-of-care testing and expanding diagnostic capabilities at primary care facilities. Related Reports: In Vitro Diagnostics (IVD) Market Size, Share, Forecast, & Trends Analysis Molecular Diagnostics Market Size, Share, Forecast, & Trends Analysis Livestock Diagnostics Market Size, Share, Forecast, & Trends Analysis IVD Reagents Market Size, Share, Forecast, & Trends Analysis About Meticulous Research® We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact: Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Visit Our Website: with us on LinkedIn- Content Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 hours ago
- Associated Press
Promethean introduces new ActivPanel D-Series digital signage and software solution
Global tech market leader combines trusted hardware and powerful software to ensure users can easily share important information and urgent messages on site SEATTLE, June 30, 2025 /PRNewswire/ -- Promethean, a leading global tech company and brand owned by Inc. (NYSE American: MYND), has announced the new ActivPanel D-Series—a non-interactive digital signage solution available this summer in the U.S. and expanding to international markets later this year. Radix Viso, a web-based management console, and Rise Vision, an all-in-one, cloud-based digital signage software platform for customers in the U.S.*, are conveniently built into the ActivPanel D-Series for immediate use with a required paid license to activate. Users can display daily information and urgent messages at a moment's notice in places like classrooms, lunchrooms, offices, huddle rooms, gyms, and more on both interactive flat panel displays (IFPDs) and digital signage solutions. 'Organizations often struggle to efficiently share and spread important information,' said Lance Solomon, chief product officer at Promethean. 'Pairing an ActivPanel D-Series with Radix Viso and Rise Vision turns any space into easy-to-manage, real-time communication hubs.' Promethean and Rise Vision provide a powerful software and display solution with more than 600 ready-to-use editable templates, remote management, and the ability to link to emergency messaging software to grab attention and help keep buildings safe and secure. The intuitive screen saver function allows users to instantly switch between display and interactive mode on an IFPD with a single tap, limiting distractions. Promethean will debut and demo the ActivPanel D-Series along with Radix Viso, Rise Vision, and more innovative products in booth number 2206 at ISTELive 2025 from June 29-July 2 in San Antonio, TX. 'The new digital signage solution and winning partnership with Rise Vision will help diversify Promethean's portfolio and create more opportunities to expand in the future,' said Solomon. 'We can make sure everyone has access to the necessary information they need, when they need it.' *Apps and software vary by region. ActivPanel D-Series does not require apps for functionality; apps are optional and require paid licenses for use. About Promethean Founded in Blackburn, England, Promethean reshapes how education organizations and modern workplaces use AV tech. A trusted leader and proven partner for over 25 years, the company's award-winning ActivPanel displays and innovative software, ActivInspire, Explain Everything, and Promethean ActivSuite™, engage students, connect colleagues, and work together seamlessly. Promethean's learning, collaboration, and communication solutions inspire users in 126 countries in various industries. Headquartered in Seattle, Washington, with offices worldwide, Promethean is a subsidiary of Inc. (NYSE American: MYND). Learn more at About Rise Vision Rise Vision, established in 1992 and found in over 11,000 organizations, specializes in cloud-based digital signage software designed to help users enhance communication and engagement. The platform enables simple creation and management of dynamic content across multiple screens. Visit for more information. ©2025 Promethean Limited. All rights reserved. Promethean, the Promethean logo, ActivPanel, ActivInspire, Explain Everything, and Promethean ActivSuite are trademarks or registered trademarks of Promethean Limited in the United Kingdom, United States, and other countries around the world. All third-party trademarks (including logos and icons) referenced by Promethean remain the property of their respective owners. Unless specifically identified, the use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between Promethean and the owners of these trademarks. Applicable Terms and Conditions for warranty and support available at All weights and dimensions are approximate. Product specifications are subject to change without notice. View original content to download multimedia: SOURCE Promethean Inc
